Planning for subgroup analysis:: a case study of treatment-marker interaction in metastatic colorectal cancer

被引:8
作者
Gönen, M [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
来源
CONTROLLED CLINICAL TRIALS | 2003年 / 24卷 / 04期
关键词
sample size; power; contrast; variance-stabilizing transformation; logistic regression; proportional hazards regression; immunohistochemistry;
D O I
10.1016/S0197-2456(03)00006-0
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Subgroup analysis is a common secondary objective in clinical trials. In oncology where the outcome is often binary (such as tumor response) or time-to-event (such as survival), subgroup analysis can be formulated using an interaction term in logistic or proportional hazards regression models. We focus on a case study of planning a randomized trial in metastatic colorectal cancer possibly involving a treatment-marker interaction. We present a method that can be used to compute the power of interaction tests for a given sample size or to compute the necessary sample sizes for a desired level of power for the planned subgroup analysis. The principle idea is borrowed from analysis of variance and uses appropriate contrasts after a variance-stabilizing transformation. This method is conceptually and operationally simple. It can be applied to binary- or ordinal-marker measurements, and existing sample size tables or software can be used. The accuracy of the approximation is shown to be reasonable by simulation studies. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:355 / 363
页数:9
相关论文
共 15 条
  • [1] COHEN J, 1988, STAT POWR ANAL BEHAV
  • [2] Thymidylate synthase expression in colorectal cancer:: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy
    Edler, D
    Glimelius, B
    Hallström, M
    Jakobsen, A
    Johnston, PG
    Magnusson, I
    Ragnhammar, P
    Blomgren, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) : 1721 - 1728
  • [3] Fleiss JL, 1981, STAT METHODS RATES P
  • [4] PLANNING SIZE AND DURATION OF A CLINICAL TRIAL STUDYING TIME TO SOME CRITICAL EVENT
    GEORGE, SL
    DESU, MM
    [J]. JOURNAL OF CHRONIC DISEASES, 1974, 27 (1-2): : 15 - 24
  • [5] Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer
    Gonen, M
    Hummer, A
    Zervouclakis, A
    Sullivan, D
    Fong, Y
    Banerjee, D
    Klimstra, D
    Cordon-Cardo, C
    Bertino, J
    Kemeny, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (03) : 406 - 412
  • [6] HABER M, 1993, BIOMETRICS, V39, P493
  • [7] Hsieh FY, 1998, STAT MED, V17, P1623, DOI 10.1002/(SICI)1097-0258(19980730)17:14<1623::AID-SIM871>3.0.CO
  • [8] 2-S
  • [9] Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
    Kemeny, N
    Huang, Y
    Cohen, AM
    Shi, WJ
    Conti, JA
    Brennan, MF
    Bertino, JR
    Turnbull, ADM
    Sullivan, D
    Stockman, J
    Blumgart, LH
    Fong, YM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (27) : 2039 - 2048
  • [10] Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer
    Kemeny, N
    Gonen, M
    Sullivan, D
    Schwartz, L
    Benedetti, F
    Saltz, L
    Stockman, J
    Fong, Y
    Jarnagin, W
    Bertino, J
    Tong, W
    Paty, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2687 - 2695